Last week, Delta 9 Bio-Tech Inc. executed an agreement with SVT Capital Corp. to list on the TSX Venture exchange via a reverse merger. Yesterday, the company filed with Sedar concerning the completion of a related $3,000,000 CAD convertible debenture "bridge loan".
About Delta 9 Bio-Tech
Delta 9 was founded in 2013 by the father and son duo Bill and John Arbuthnot. The company was initially licensed by Health Canada in March of 2014, and currently holds cultivation, sale and starting materials licenses pursuant to the ACMPR.
The company is currently utilizing 15,000 square feet of their 80,000 square foot licensed facility. Delta 9 cultivates their cannabis using hydroponics, although initially they used geoponics (soil) as their primary cultivation method. Delta 9 is also in the process of opening a cannabis clinic. Currently, Delta 9 serves 1,300 registered patients across Canada and offers a rotation of around 15 strains.
Now, the first day of trading for Delta 9 is still a long way down the road (the company expects it to happen sometime in the fall), but we eagerly await another publicly listed LP. If you can't wait till fall for Delta 9, check out our database of publicly traded LPs here, and be sure to check out MedReleaf that just started trading on the TSX today.
Be sure to subscribe to our free Canadian licensed producer email newsletter so you never miss an important update. Also, visit us on Facebook, Twitter and Instagram!
Investing in nanocap, microcap, and small cap stocks is highly speculative. The publishers of DailyMarijuanaObserver.com are not registered as Investment Advisors or Broker-Dealers in any jurisdiction whatsoever. The information contained on DailyMarijuanaObserver.com (“this site”) has been prepared solely for informational purposes. Nothing on the site is an offer or solicitation to buy or sell securities. Investors should seek financial advice regarding the appropriateness of investing in any securities mentioned from their financial advisor.